The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Imaging: A miliary pattern (diffuse random micronodules)
Publications
Complications of Intravesical BCG Immunotherapy for Bladder Cancer.
Radiographics : a review publication of the Radiological Society of North America, Inc 2019 Jan-Feb;39;80-94 — 2019 Jan-Feb — 80-94
[Dyspnea after instillation therapy for bladder cancer].
Der Radiologe 2018 May;58;482-486 — 2018 May — 482-486
Miliary Tuberculosis that Developed after Intravesical Bacillus Calmette-Guerin Therapy.
Internal medicine (Tokyo, Japan) 2017;56;1563-1567 — 2017 — 1563-1567
Subclinical miliary Mycobacterium bovis following BCG immunotherapy for transitional cell carcinoma of the bladder.
BMJ case reports 2014 May 08;2014; — 2014 May 08
Miliary tuberculosis after intravesical bacille Calmette-Guérin immunotherapy for carcinoma of the bladder.
AJR. American journal of roentgenology 1999 Mar;172;748-50 — 1999 Mar — 748-50
Miliary lung disease after intravesical bacillus Calmette-Guérin immunotherapy.
Radiology 1996 Oct;201;43-4 — 1996 Oct — 43-4
T helper cell alveolitis after bacillus Calmette-Guerin immunotherapy for superficial bladder tumor.
The Journal of urology 1994 Jun;151;1634-7 — 1994 Jun — 1634-7